Top Metoprolol Succinate Brands: Leading Choices for Reliable Heart Health

Metoprolol succinate, a popular medication for managing high blood pressure and heart conditions, is available from a variety of reputable pharmaceutical companies. Among the top brands known for their quality production and effectiveness are AstraZeneca's Toprol-XL, which has long been trusted by healthcare professionals for its consistent performance. Additionally, Teva Pharmaceuticals offers a generic version that has gained significant market presence due to its affordability and reliability. Furthermore, Dr. Reddy's Laboratories has also established a strong foothold with its competitive pricing and stringent quality checks. To find out more about these top brands and what makes them stand out, explore the information provided below.

Illustration of metoprolol succinate

Best brands of metoprolol succinate in 2025

Toprol-XL

Toprol-XL, manufactured by AstraZeneca, is a leading brand for metoprolol succinate, a beta1-selective adrenoceptor blocking agent, formulated as extended-release tablets for once-daily administration. It is available in doses of 25, 50, 100, and 200 mg, providing a controlled and predictable release of metoprolol. The global Metoprolol Succinate market, which includes Toprol-XL, is expected to grow at a CAGR of 4.70% from 2024 to 2031, with North America holding over 40% of the global revenue. The product's bioavailability is 77% relative to conventional metoprolol, and it has been shown to provide comparable total beta1-blockade over 24 hours. Generic versions, such as the one approved for Lupin Limited in August 2023, also contribute to the market's expansion. To learn more about Toprol-XL, you can view the FDA documentation.

Mylan Pharmaceuticals

Mylan Pharmaceuticals is a prominent producer of metoprolol succinate, contributing significantly to the global market. As of 2024, Mylan is one of the key competitors in the metoprolol succinate market, alongside AstraZeneca and Teva Pharmaceuticals. The company's generics of metoprolol succinate account for a substantial portion of the approximately 40 million prescriptions filled annually in the U.S., with generics making up about 90% of these prescriptions. Mylan's involvement in the market is crucial, especially given the high prevalence of cardiovascular diseases and the growing demand for effective cardiovascular treatments. The global metoprolol succinate market, in which Mylan participates, is expected to grow at a CAGR of 4.70% from 2024 to 2031. For more information, visit Mylan Pharmaceuticals.

Sandoz

Sandoz, a renowned pharmaceutical company, is a significant producer of metoprolol succinate, contributing to the global market with its high-quality formulations. In the metoprolol succinate market, North America holds a major share, with the US being a key region, and Sandoz plays a crucial role in this segment. The global metoprolol succinate market is expected to grow at a CAGR of 4.70% from 2024 to 2031, driven by the increasing prevalence of cardiovascular diseases. Sandoz, along with other major players like AstraZeneca and Novartis, focuses on developing innovative formulations and expanding product portfolios. The hypertension segment, which accounts for over 50% of the total revenue, is a key area where Sandoz's metoprolol succinate extended-release tablets are widely used.

Teva Pharmaceuticals

Teva Pharmaceuticals is a leading producer of metoprolol succinate, offering a generic version of Toprol-XL® Extended Release Tablets, which is highly competitive in the market. The global metoprolol succinate market, where Teva is a key player, is expected to grow at a CAGR of 4.7% from 2024 to 2031, with North America holding over 40% of the global revenue. Teva's product is part of a market segment that saw hypertension accounting for over 50% of the total revenue in 2020. The company's focus on developing new formulations and expanding product portfolios strengthens its market position. Teva's generic metoprolol succinate extended-release tablets are widely used in hospital pharmacies, retail pharmacies, and online pharmacies.

Lupin Pharmaceuticals

Lupin Pharmaceuticals stands out as a leading producer of metoprolol succinate, having received approval from the U.S. FDA in August 2023 to market a generic version of Toprol-XL® extended-release tablets in doses of 25 mg, 50 mg, 100 mg, and 200 mg. This approval reinforces Lupin's commitment to providing affordable generic medications, particularly in the cardiovascular market. The product will be manufactured at Lupin's Pithampur facility in India, highlighting the company's global manufacturing capabilities. With estimated annual sales of USD 305 million in the U.S. for Toprol-XL® (as of June 2023), Lupin's entry is expected to significantly impact the market. The global metoprolol succinate market, which includes Lupin, is projected to grow at a CAGR of 4.70% from 2024 to 2031. For more information, visit their official announcement on Lupin's website.

Sun Pharma

Sun Pharmaceutical Industries Limited is a leading producer of metoprolol succinate, offering an extended-release capsule formulation that is bioequivalent to the Reference Listed Drug (RLD) TOPROL-XL®. This formulation is available in 25 mg, 50 mg, 100 mg, and 200 mg strengths and is indicated for hypertension, angina pectoris, and heart failure. The capsules can be administered orally once a day, with a maximum daily dose of 400 mg, and can also be sprinkled over food or administered through nasogastric tubes for patients with dysphagia. Sun Pharma's submission for this product was approved by the FDA in 2018, following a thorough review process. The company's efforts in developing this formulation have contributed to its strong presence in the cardiovascular medication market. For more detailed information, you can view their FDA submission document.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a leading manufacturer and supplier of Metoprolol Succinate API, known for its high-quality and reliable production. The company launched Metoprolol Succinate extended-release tablets in the US market in 2012, available in strengths of 25 mg, 50 mg, 100 mg, and 200 mg, which are generic versions of AstraZeneca's Toprol-XL tablets. These tablets had significant sales, with Toprol-XL and its generics generating nearly $1.13 billion in the US for the 12-month period ending June 2012. Dr. Reddy's successfully increased their production capacity by 50% to meet demand, reducing quality control waiting time from 11 days to 6 and machine cleaning time from 21 hours to 13.

Watson Pharmaceuticals

Watson Pharmaceuticals is renowned as a leading producer of metoprolol succinate, having received FDA approval for its generic version of Toprol XL in 2009. The company's metoprolol succinate extended-release tablets, available in 25 mg and 50 mg strengths, are used to treat conditions such as angina, heart failure, and high blood pressure. Notably, Watson was awarded market exclusivity as the first generic applicant for the 50 mg strength, although it later relinquished this exclusivity to allow Sandoz to enter the market. The generic equivalents of Toprol XL had annual sales of approximately $628 million for the 12 months ending June 2009, highlighting the significant market presence of Watson's product. For more information, you can visit the FDA approval details on Watson Pharmaceuticals.

Novartis

Novartis is a leading producer of metoprolol succinate, contributing significantly to the global market. In 2020, the hypertension segment, where metoprolol succinate is widely used, held over 50% of the total revenue in the metoprolol succinate extended-release tablets market. Novartis, along with other key players like AstraZeneca and Teva Pharmaceutical Industries, dominates the market due to its extensive product portfolios and global distribution networks. The company focuses on developing innovative formulations and strategic partnerships to strengthen its market position. The global metoprolol succinate extended-release tablets market is expected to reach USD 2.5 billion by 2033, growing at a CAGR of 5.2% during the forecast period.

Aurobindo Pharma

Aurobindo Pharma is recognized as one of the leading producers of Metoprolol Succinate, a selective b1-blocker used to treat hypertension, heart failure, and chest pain. The company's Metoprolol Succinate formulations, including sustained-release tablets, have been developed using advanced techniques such as 32 factorial design to optimize drug release profiles. Aurobindo Pharma's commitment to quality and innovation has contributed to the global Metoprolol Succinate market, which was valued at roughly 78 thousand tonnes in 2023 and is anticipated to grow at a CAGR of 3.4% during the forecast period. Their formulations have shown promising dissolution parameters, such as a 40 mg HPMCK100M formulation achieving specific release times (t10%= 0.564h, t50% = 3.713 h, t75% = 7.426 h, t90% = 12.339 h). This precision in formulation underscores Aurobindo Pharma's position as a reliable and efficient producer in the pharmaceutical industry. For more information, visit their official website.